TLDR
- AbbVie received FDA approval for Juvmo (tavapadon), a new Parkinson’s disease treatment.
- Juvmo is the first selective D1/D5 receptor agonist approved for the condition.
- The drug is taken once daily and can be used with or without levodopa.
- Approval was based on Phase 3 TEMPO trial data showing improved daily functioning.
- AbbVie plans to launch Juvmo in the U.S. in October 2026.
AbbVie stock (ABBV) slipped slightly on Monday, down 0.29%, after the company announced a major regulatory win. The FDA approved Juvmo, a new drug for Parkinson’s disease.
Juvmo is the brand name for tavapadon. It’s a once daily tablet designed to help control motor symptoms in adults with Parkinson’s.
This approval matters because Juvmo works differently than existing options. It’s the first and only selective D1/D5 receptor agonist approved for Parkinson’s disease.
Most current dopamine agonists target D2/D3 receptors instead. Those drugs can come with tolerability issues that limit how doctors use them.
AbbVie says Juvmo gives doctors a new tool. It can be taken alone or alongside oral levodopa, the standard treatment for Parkinson’s.
Why This Approval Stands Out
Levodopa remains the backbone of Parkinson’s treatment. But many patients need higher and more frequent doses as the disease progresses.
That escalation isn’t free. It can lead to complications like dyskinesia, which are involuntary movements that affect quality of life.
According to AbbVie, about 70% of Parkinson’s patients see their levodopa dose increased within the first year of treatment. Juvmo may help slow that trend.
In the TEMPO clinical trial program, results looked promising. After 85 weeks on Juvmo, 93% of participants hadn’t needed to increase their levodopa dose.
For patients with early Parkinson’s, 94% hadn’t started levodopa at all after the same period. Those numbers come from the open label extension phase of the trial, called TEMPO-4.
What the Trial Data Showed
The TEMPO-1 study measured daily living scores using a standard Parkinson’s rating scale. Patients on Juvmo saw a 22 to 23% improvement compared to baseline.
The placebo group, meanwhile, got worse by 12%. That gap was statistically significant across both tested doses.
In TEMPO-3, which looked at patients already on levodopa, Juvmo increased “on” time without troublesome dyskinesia. Patients gained 1.7 hours of on time versus 0.6 hours for placebo.
“Off” time, when symptoms return, also dropped more sharply with Juvmo. Patients saw a 1.9 hour reduction compared to 0.9 hours for placebo.
Side effects were mostly mild to moderate. The most common included nausea, headache, dizziness, and fatigue.
For patients combining Juvmo with levodopa, dyskinesia and hallucinations also showed up as common side effects. AbbVie noted the overall safety profile was described as favorable.
Roopal Thakkar, AbbVie’s chief scientific officer, called this the first major dopaminergic breakthrough for Parkinson’s in decades. That’s a notable claim given how long the treatment landscape has stayed static.
Outside voices echoed the sentiment. Hubert Fernandez, a neurologist at Cleveland Clinic who worked on the TEMPO trials, said the approval gives doctors more flexibility to tailor treatment.
The Michael J. Fox Foundation also weighed in. Its chief scientist, Brian Fiske, called the approval an important step in building out treatment options for Parkinson’s patients.
AbbVie confirmed Juvmo will be available to patients in the U.S. starting in October 2026. That’s just weeks away from today’s announcement.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
